MedTrace Logo

A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

NCT04515849 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2025-01-17

Study results available
· View outcomes & findings →

Summary

A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.

Conditions

Interventions

DRUG

Cotadutide 100 micrograms

Cotadutide 100 micrograms administered subcutaneously

DRUG

Cotadutide 300 micrograms

Cotadutide 300 micrograms administered subcutaneously

DRUG

Cotadutide 600 micrograms

Cotadutide 600 micrograms administered subcutaneously

DRUG

Semaglutide

Semaglutide 1.0 miligrams administered subcutaneously

DRUG

Placebo

Placebo administered subcutaneously

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-31
Primary Completion
2022-03-08
Completion
2022-03-08

Countries

  • Australia
  • Canada
  • Germany
  • Japan
  • New Zealand
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04515849 on ClinicalTrials.gov